Teleflex Announces $2.03 Billion Business Sale Agreements

Teleflex ( (TFX) ) has provided an announcement.

On December 9, 2025, Teleflex announced agreements to sell its Acute Care, Interventional Urology, and Original Equipment Manufacturing (OEM) businesses for a total of $2.03 billion in cash. The transactions are expected to close in the second half of 2026, subject to regulatory approvals. The proceeds will be used for share repurchases and debt reduction, enhancing Teleflex’s financial flexibility and allowing it to focus on its core critical care and high acuity hospital markets. The company’s Board of Directors has also authorized a $1 billion share repurchase program, reflecting confidence in Teleflex’s strategic direction and growth potential.

The most recent analyst rating on (TFX) stock is a Hold with a $127.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Spark’s Take on TFX Stock

According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.

Teleflex’s overall stock score reflects a mixed financial performance with strong revenue growth but profitability challenges. Technical analysis shows a neutral outlook, while valuation is constrained by recent losses. The earnings call provides a positive future outlook with expected revenue growth and improved margins, balancing current operational pressures.

To see Spark’s full report on TFX stock, click here.

More about Teleflex

Teleflex Incorporated is a global provider of medical technologies, offering a diverse portfolio of solutions in anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. The company is known for its trusted brands such as Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, and Weck.

Average Trading Volume: 598,802

Technical Sentiment Signal: Sell

Current Market Cap: $5.33B

Find detailed analytics on TFX stock on TipRanks’ Stock Analysis page.